In particular, when classifying Keap1/NFE2L2 mutations into different groups: Nrf2-activating MU, Nrf2-inactivating MU, unknown NFE2L2 MU and WT groups, it was observed that most immunotherapy-blocked genes were lower expressed, and there was a low enrichment of tumor-related immune cells, TCR richness, and Shannon diversity in Nrf2-activating MU group. The gene discussed is NFE2L2; the disease is neoplasm.